News | December 04, 2007

Study: Blood Flow in Cervical Tumors Can Predict Outcome

December 5, 2007 - Measuring both the level of red blood cells in the body and the blood flow in tumors can help predict which cervical cancer patients are likely to have a better outcome, according to researcher from the Ohio State University Comprehensive Cancer Center presented at the American Society of Therapeutic Radiology and Oncology in Los Angeles.

“We must look at how the oxygenation in the circulation and the vasculature of each individual tumor interact,” says Dr. Nina Mayr, a researcher and chair of radiation medicine at the James Cancer Hospital and Solove Research Institute at Ohio State University. “For cancer therapy to be effective, tumors must have blood flow and sufficient oxygen. We have identified a method using magnetic resonance imaging (MRI) to check the actual blood flow within tumors as they are treated. If we put together both the number of red blood cells that a patient’s body has to carry the oxygen to the tumor, and the blood flow within the tumor, we have a powerful predictor to tell us whether the treatment will work."

Researchers analyzed the levels of red blood cells throughout the course of radiation and chemotherapy in 66 cervical cancer patients. In addition, they examined the blood supply of the tumor during therapy in each patient using innovative MRI techniques. The level of red blood cells has long been thought to influence the response of tumors to radiation therapy and chemotherapy. Red blood cells contain hemoglobin, which carries the oxygen from the lungs to the tissue. Low red blood cell levels have been implicated in poor treatment response in cervical cancer patients – probably due to poor oxygen supply, which impairs the tumor-killing effects of radiation, Mayr says.

“We found that we must analyze both the level of red blood cells and the vasculature ‘signature’ of each individual tumor,” Mayr says. “If both are high, patients responded well to therapy and had a 91 percent chance of survival. But when both are low, patients had a 32 percent chance of tumor recurrence, and only a 56 percent chance of survival.”

Patients often receive transfusions or stimulating factors that boost their low red blood cell levels, but those treatments can be expensive, uncomfortable and somewhat risky, says Mayr, also holder of the Max Morehouse Chair in Cancer Research at Ohio State.

“Now we may have a way to predict whether that treatment will work for each individual patient,” Mayr says. “This new information may help to make cancer care more personalized by using transfusions in patients who need them most, and we may be able to avoid them in those who will do well without them.”

The study also involved Ohio State researchers Jian Wang, Dongqing Zhang, Joseph Montebello, John Grecula, Jeffrey Fowler and William Yuh.

For more information: www.medicalcenter.osu.edu

Related Content

MR-HIFU, ThermoDox, combination therapy, recurrent childhood tumors, Celsion, Children's National Health System, Phase I clinical study
News | Oncology Related Products | December 19, 2016
December 19, 2016 — Children’s National Health System and Celsion Corp.
News | Clinical Decision Support | October 27, 2016
October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use
contrast-enhanced ultrasound, CEUS, liver cancer, hepatocellular carcinoma, study, Advances in Contrast Ultrasound conference, ICUS
News | Ultrasound Imaging | September 12, 2016
September 12, 2016 — Tiny microbubbles are being used to more effectively...
cardio-oncology, echo strain assessment, echoinsight, epsilon

Epsilon's EchoInsight software helps analyze cardiac function by evaluating wall motion strain. 

Feature | Cardio-oncology | May 13, 2016 | Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat
Carestream, Clinical Collaboration Platform, Fox Valley Hematology & Oncology
News | Enterprise Imaging | April 20, 2016
Fox Valley Hematology & Oncology (Appleton, Wis.) implemented Carestream’s Vue for Clinical Collaboration Platform...
cancer immunotherapy, development, Axel Hoos, Nature Reviews, imaging
News | Oncology Related Products | March 31, 2016
In a paper published in Nature Reviews last week, Axel Hoos, M.D., Ph.D., laid out the current immunotherapy...
Pyrexar, buy back outside ownership, Person Medical, BSD-2000 Hyperthermia System

BSD-2000 image courtesy of Pyrexar Medical

News | Oncology Related Products | March 15, 2016
Pyrexar announced it has purchased back outside ownership from Person Medical (formerly BSD Medical), concluding a...
BTG, LC Bead LUMI, radiopaque embolic bead, Philips Healthcare, Live Image Guidance, liver cancer
News | Interventional Radiology | February 09, 2016
BTG plc and Royal Philips announced a significant milestone in their collaboration with the treatment of the first...
Overlay Init